Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Jul 30, 2012 (14 years ago)

Trastuzumab Kit containing 1 vial Trastuzumab

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Presence of Particulate Matter: One lot of Bacteriostatic Water for Injection, USP diluent vials that were packed with Trastuzumab Kits for investigational use has the potential to contain glass particulates.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Trastuzumab Kit containing 1 vial Trastuzumab (nominal content: 440 mg); 1 20 mL multiple dose vial Bacteriostatic Water for Injection, USP (1.1% benzyl alcohol), Manufactured by Hospira, Inc., for Genentech, Inc., South San Francisco, CA 94080-4990, NDC 50242-903-69; and 1 Reconstitution Instructions per kit; Investigation Use only, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080-4990.

Affected NDC 50242-0903-69

Compare with the code on your package — it is the most precise check available.

Drug: Alcohol

Recalling firm
Genentech Inc
NDC code
50242-903-69
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-135-2013 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Alcohol recalls

See all

Other recalls by Genentech Inc

All 2012 recalls
Class II · Moderate risk

Cathflo activase

Lack of Assurance of Sterility: Deformed stoppers observed during filling operations for Cathflo Activase.

Terminated Sterility / contamination Genentech, Inc. NDC 50242-041-64 D-0509-2024
Class III · Low risk

Susvimo (ranibizumab injection)

Defective Delivery System: Commercial implants do not meet the filed specification for the intended use, a few patients have experienced an issue with the implants that renders it non-functioning.

Terminated Packaging defect Genentech Inc NDC 50242-078-55 D-0025-2023
Class II · Moderate risk

Xolair (omalizumab)

Failed Stability Specifications: Out of Specification results of Polysorbate 20 (PS20) content were detected at the 12 month testing time point.

Terminated Stability / shelf life Genentech Inc D-0650-2021
Class III · Low risk

Evrysdi (risdiplam)

Defective Container: complaints received regarding some incorrect press-in-bottle-adapters (PIBA), the incorrect PIBAs have a female instead of male fit so they cannot be used in combination with co-packed syringes.

Terminated Packaging defect Genentech Inc D-0357-2021